Hematopoietic stem cell transplantation is the best way to cure this disease.
Chemotherapy: drug treatment of diseases caused by pathogenic microorganisms, parasites and malignant tumors (chemotherapy for short).
Chemotherapy refers to the application of drugs to treat cancer. These special drugs can kill tumor cells and are sometimes called cytotoxic drugs. Many chemotherapy drugs come from nature, such as plants, others are synthetic. At present, there are more than 50 kinds of chemotherapy drugs such as epirubicin, adriamycin, daunorubicin, mitomycin and fluorouracil deoxynucleoli. These drugs are often used in combination with different intensities.
How is chemotherapy given?
Some chemotherapy drugs are taken in the form of tablets, others are injected by intramuscular injection or subcutaneous injection, as well as intraspinal injection (intrathecal injection), and more commonly intravenous injection. Intravenous injection can be completed in a few minutes, or it can be placed in a large volume of liquid for several hours. Sometimes several drugs are used at the same time.
What type of chemotherapy is used?
It depends on the type of tumor, the spread distance and the overall health of the patient. Every patient is different, and the treatment for each patient is specially designed, which also shows that each patient's response to treatment is different.
Can chemotherapy cause pain?
Generally speaking, chemotherapy is painless, and some drugs will have a burning sensation when infused intravenously. If this happens, please tell the nurse or doctor immediately, because the medicine will damage the tissue around the vein when it leaks. Chemotherapy can often be carried out in outpatient clinics, and patients do not have to spend the night in hospitals.
How long does the treatment (chemotherapy) last
Chemotherapy is generally administered in one course of treatment, and the course of treatment can be interrupted to allow normal cells to recover. The intermission period is 1 week or several weeks, depending on the type of drug or the application of the drug. The number of courses depends on the type of treatment and the purpose of treatment (curing or controlling cancer).
How do you know that chemotherapy is effective?
Doctors need several months to judge the effect of your treatment. Patients should undergo physical examination, blood test and X-ray examination. You can ask your doctor about the test results and information to remind you of the progress of your illness. Generally speaking, people seldom mention side effects. Sometimes people think that if there are no side effects, drugs will have no effect. Or if there are side effects, this medicine is very effective. But the side effects are not necessarily the same for every patient, and whether there are side effects is usually not a signal of whether the treatment is effective or not.
Can I use other drugs during chemotherapy?
Some drugs will interfere with your chemotherapy effect. Before starting chemotherapy, show the doctor the list of drugs you use, including laxatives, cold medicines, painkillers and vitamins. Before starting the treatment, the doctor will tell you whether to stop taking these drugs. After starting treatment, taking any new drugs or stopping taking drugs must be checked by a doctor.
Can I go to work during chemotherapy?
Generally speaking, you can't go to work during chemotherapy, but you can do appropriate exercise according to your physical condition, such as walking and playing Tai Ji Chuan. You can also read newspapers and listen to music.
Chemotherapy is an effective means of tumor treatment, but almost all chemotherapy drugs will cause patients with varying degrees of loss of appetite, nausea, vomiting and so on. , thus weakening the nutritional status of patients. A reasonable diet can prevent and reduce weight loss and malnutrition caused by treatment.
1. Before chemotherapy:
Balanced diet before chemotherapy, including cereals (rice and pasta), vegetables and fruits (about 600-800g), meat, poultry, eggs (about 50- 100g lean meat or chicken or fish, 1 egg), milk and bean products (a bag of milk, 50-1egg)
Eat food with low fat, high carbohydrate, high vitamins and minerals the day before chemotherapy. Choose rice, pasta, fish, chicken, eggs, lean meat, tofu, vegetables and fruits.
2. In chemotherapy:
Nourishing yin and invigorating spleen porridge: it can relieve symptoms such as loss of appetite, dry mouth and fatigue during chemotherapy. The preparation method is to add 20 grams of longan, 20 grams of lotus seeds, 50 grams of yam, 50 grams of coix seed and japonica rice, and add water to cook porridge.
Try not to eat your favorite food within 24 hours after chemotherapy, because it will affect your feeling about this food in the future.
Dietary requirements are low fat, high carbohydrate and a small amount of high quality protein. The daily diet is mainly cereals, vegetables and fruits, supplemented by digestible chicken, fish and eggs, and protein powder (soybean or egg white) can be supplemented appropriately. Less oil.
If the treatment response is heavy, the diet is mainly liquid. You can eat vegetable soup, rice soup, fruit juice and some elements.
Chewing ginger has a certain antiemetic effect.
3. After chemotherapy:
Chemotherapy is the most advanced treatment method in tumor treatment in recent years. Chemotherapeutic drugs are often "unclear" and "indistinguishable from the enemy", killing both tumor cells and normal human cells. A large number of clinical practices have proved that high-dose radiotherapy and chemotherapy for patients in the middle and late stage, or chemotherapy for drug-resistant patients, can only lead to weaker life and accelerate the death of patients. It can often be seen in a large number of outpatient clinics that the death of patients is not caused by cancer itself, but by unscientific and inappropriate lethal treatment. For example, after multiple interventional treatments for liver cancer, liver failure such as ascites and jaundice occurred and died; Pleural effusion died of respiratory failure after chemotherapy for lung cancer; After chemotherapy for gastric cancer and intestinal cancer, nausea and vomiting make patients more tired and die. Leukocyte decline, patients died of infection, etc. For the treatment of advanced cancer, it is more important to relieve the pain, improve the quality of life, control the disease, and "strive for progress steadily" in order to obtain "long-term survival with tumor". Chinese herbal medicine with Taxus as the main component is the first choice for cancer treatment. Taxus chinensis is an endangered anticancer plant in the world. It is the only Chinese herbal medicine that can treat cancer in the world at present, and is praised as "the last line of defense for patients with advanced cancer" by world experts. The implication is that yew is the only hope and real life-saving straw for cancer patients. However, yew is very toxic. After taking it, it may cause serious toxic and side effects such as suppression of hematopoietic function of bone marrow and leukopenia, mainly manifested as dizziness, dilated pupils, nausea, vomiting, diffuse abdominal pain and myasthenia. In severe cases, bradycardia, cardiac arrest or death occur! It is safe and effective only if it is compatible with Chinese herbal medicines to eliminate its toxicity.
Dietotherapy: Jujube, longan and wolfberry porridge: It has the effects of invigorating spleen and kidney, filling marrow and generating blood, and is suitable for patients with reduced hemogram after chemotherapy. The preparation method comprises boiling Fructus Jujubae 10, Arillus Longan15g, Fructus Lycii15g, Coicis Semen100g, and crystal sugar10g with water.
If you are weak after chemotherapy, you should choose nutritious and digestible foods, such as soft rice, porridge, bread, steamed bread, steamed buns, fish, eggs, chicken, soup, potatoes, bananas and jam.
Eat less and eat more.
Ginger can be used to stimulate appetite.
If you lose weight significantly, you can use an elemental diet.
Use yogurt instead of milk to avoid flatulence.
Proper exercise.
Bone marrow transplantation is mainly used to treat these diseases.
Bone marrow transplantation is a very advanced treatment method, which is mainly used to treat acute and chronic leukemia, severe aplastic anemia, thalassemia, lymphoma and multiple myeloma. Now, further attempts are being made to treat metastatic breast cancer and ovarian cancer.
The source of bone marrow
Bone marrow transplantation can be divided into autologous bone marrow transplantation and allogeneic bone marrow transplantation. As the name implies, the bone marrow of autologous bone marrow transplantation comes from the patient himself, and the bone marrow of allogeneic bone marrow transplantation comes from donation.
Therapeutic effect of allogeneic bone marrow transplantation
First, acute leukemia
The advantages of bone marrow transplantation over ordinary chemotherapy have been fully reflected in acute leukemia, and this therapy can significantly improve the disease-free survival rate of patients with acute leukemia. According to the analysis of a large number of cases by Fred Hutchinson Cancer Research Center and IBMTR, the 3-year disease-free survival rate of AML can reach about 50% after receiving ALLo-BMT for the first time. The 3-year disease-free survival rate of patients undergoing chemotherapy at the same time is only 18-27%. The curative effect of BMT is influenced by many factors, mainly including:
1.Timing of BMT: The first remission of BMT is better than the second remission. Brotint et al. (1988) Comparing the BMT results of AL patients in the first remission stage and the second pause stage, it was found that the 5-year recurrence rate of patients after BMT in the first remission stage was 21%1%,and the 5-year disease-free survival rate was 46% 9%. The 5-year recurrence rate and survival rate of patients after BMT in the second remission stage were 56% and 22%, respectively. Data from IBMTR and Seattle have similar results. Therefore, patients with acute leukemia should enter BMT in the first complete remission period.
2. The nature of the disease itself: the relationship between the curative effect of BMT and the classification is not clear, and it seems that the curative effect of AML is better than that of ALL. For all patients, the following indicators can be considered as high risk factors: (1) the age is less than 2 years old or older than 15 years old, and the peripheral white blood cells at the time of initial diagnosis are > 50×109/L; (2) Central nervous system leukemia; (3)T-cell type or ALL(4 with special cytogenetic changes (4) For AML patients, the white blood cell count at the initial diagnosis is more than 75× 109/L, or patients with M4 and M5 have poor prognosis.
3. Patient's age and general situation: The older the patient, the worse the organ function, and the greater the possibility of various complications after BMT, especially GVHD. Therefore, allogeneic bone marrow transplantation should be cautious for patients over 45 years old, and generally not for patients over 50 years old.
Second, chronic myeloid leukemia
Allogeneic bone marrow transplantation (BMT) is the only treatment for chronic myeloid leukemia. The five-year disease-free survival rate of patients with chronic CML after allogeneic bone marrow transplantation can reach 60-90%. Even in the same chronic phase, the BMT effect within 17 months after diagnosis is better than that within 17 months after diagnosis. The younger the patient is, the better the curative effect is, and the curative effect of taking hydroxyurea before transplantation is better than taking busulfan. Domestic statistical results show that the long-term disease-free survival rate of patients with chronic CML after receiving sibling allogeneic bone marrow transplantation with the same HLA matching is 80%, and the allogeneic efficacy of patients with accelerated or acute CML is not as good as that of patients with chronic CML.
Third, malignant lymphoma: first consider autologous bone marrow transplantation.
4. Multiple myeloma: In the past, it was considered that MM patients were not suitable for BMT. With the development of supportive treatment and the emergence of young patients, the number of successful cases of MM BMT has gradually increased. According to the data of IBMTR, European Bone Marrow Transplantation Office and Ferd Hutchsin Cancer Research Center, about 150MM patients in the world received bone marrow transplantation, and the disease-free survival rate of those who received BMT in the first remission period reached 69%.
Five, myelodysplastic syndrome (MDS) BMT treatment of MDS can make the 3-year disease-free survival rate of patients close to 50%, and a considerable part can be cured, especially for young patients who have received BMT in the early stage.
Severe aplastic anemia (SAA) is the disease that receives the most BMT among non-tumor diseases. If the patient has not received BMT blood transfusion, the long-term survival rate can reach 80%.
Others: hereditary immunodeficiency disease, thalassemia, etc.
Clinical efficacy of autologous bone marrow transplantation (ABMT)
First, leukemia
I) acute leukemia
Although allogeneic transplantation has a good effect on acute leukemia, the lack of suitable donors and high transplantation cost limit most patients. Autologous bone marrow transplantation, as an alternative treatment for allogeneic transplantation, has developed rapidly in recent years. At present, although a large number of clinical data have been accumulated, the status of autologous bone marrow transplantation in the treatment of acute leukemia is still controversial because of the far different curative effects reported by various reports. Taking acute lymphoblastic leukemia as an example, the long-term leukemia-free survival rate (LFS) of autologous bone marrow transplantation in the first complete remission period ranges from less than 30% to over 70%. Some data show that autologous bone marrow transplantation can not improve LFS in patients with acute lymphoblastic leukemia, but some data also show that the effect of autologous bone marrow transplantation on acute lymphoblastic leukemia in complete remission for the first time is close to that of allogeneic bone marrow transplantation, and it is far better than that of chemotherapy alone. A similar situation exists in acute myeloid leukemia. Lowebery et al reported that 32 cases of acute myeloid leukemia received unpurified autologous bone marrow transplantation in the first remission stage, and the 3-year recurrence-free survival rate was only 35%, while Italian scholars also received unpurified autologous bone marrow transplantation in the first remission stage to treat 55 cases of acute myeloid leukemia, and the 8-year survival rate was 49% higher, which was not significantly different from the survival rate of 104 cases of allogeneic bone marrow transplantation in the same period (52%). Recently, Memet and others reported the results of their prospective comparative study on chemotherapy or autologous bone marrow transplantation in the treatment of acute leukemia: the LFS of autologous bone marrow transplantation and chemotherapy for more than 3 years in acute myeloid leukemia group were 55% and 34%, respectively, and that in acute lymphoblastic leukemia group was 48% and 22%. This shows that the curative effect of transplantation is better than that of single transplantation.
Chemotherapy group. Cahn et al. counted11/patients with acute myeloid leukemia over 50 years old who received autologous bone marrow transplantation in the initial complete remission stage, and their 4-year LFS was 34% 5%. Although it is not as good as similar patients under 50, it is better than chemotherapy, so it is advocated that patients over 50 should also consider autologous bone marrow transplantation after complete remission. The difference in the curative effect of autologous bone marrow transplantation in the treatment of acute leukemia in the literature is mainly due to the differences in patients' condition, chemotherapy before transplantation, pretreatment scheme and supporting treatment conditions, and the lack of representativeness of cases treated by each family. The curative effect of European Autologous Bone Marrow Transplantation Registry 1992 (see the table below) is due to a large number of cases, which can represent the objective curative effect of autologous bone marrow transplantation in various transplant units. The curative effect is slightly lower than that of 1993 acute leukemia patients in the first remission stage (52% 4% in acute myeloid leukemia group and 50% 5% in acute lymphoblastic leukemia group), but the LFS of patients in the second remission stage is the same.
Therapeutic effect of autologous bone marrow transplantation on acute leukemia (1992)
The number of leukemia cases at the time of classification and transplantation was 8 years LFS.
AML standard risk Cr 1 692 4 1% 3%
High risk Cr 1 264 44% 3%
Chromium 2 305 33% 3%
All standard risks Cr 1 280 42% 3%
High risk Cr 1 1 74 40% 4%
CR2 357 3 1% 3%
At present, most scholars believe that acute lymphoblastic leukemia with good prognosis does not need autologous bone marrow transplantation in the first complete remission period, while high-risk acute lymphoblastic leukemia with no recurrence after complete remission is better. Once acute lymphoblastic leukemia recurs, the long-term survival rate of chemotherapy alone after the second remission is very low, while autologous bone marrow transplantation can make 1/3 patients survive for a long time. One group reported that the LFS of children with acute lymphoblastic leukemia in the first remission was 865,438+0% within three years after autologous bone marrow transplantation, while that of patients with acute lymphoblastic leukemia was only about 65,438+00% within less than two years. Maintenance treatment for patients with high risk of recurrence after transplantation may be beneficial to reduce recurrence. When to perform autologous bone marrow transplantation for acute myeloid leukemia, except for a few subtypes with better chemotherapy effect, such as M3, most people think that autologous bone marrow transplantation should be performed in the first complete remission period. Bone marrow collected by Seattle Transplantation Center in the first remission stage of acute myeloid leukemia was cryopreserved. Once the patient showed signs of recurrence, he was immediately pretreated with a scheme containing busulfan, and then the previously frozen bone marrow was reinfused. The recurrence-free survival rate is about 40%. Patients with acute myeloid leukemia who have achieved the second complete remission should take the time to undergo autologous bone marrow transplantation.
What is the prospect of autologous bone marrow transplantation to cure acute leukemia? In order to answer this question, the European Bone Marrow Transplantation Collaborative Group specially counted the LFS and recurrence rate of patients with autologous bone marrow transplantation who did not relapse within 2 years after transplantation from 1979 to 1999. The results are shown in the following table. These data show that those who do not relapse within 2 years after transplantation, although a few patients will relapse later, most patients may have been cured.
The prospect of no recurrence 2 years after autologous bone marrow transplantation.
The recurrence rate of LFS in leukemia type transplantation (%) and the recurrence rate of the latest recurrence (%) (year)
AML CR 1 77 14 6
CR 2-3 84 12 5. 1
All CR 1 84 15 5.3
CR2-3 79 19 4.9
The above table is the statistical data of European bone marrow transplantation collaboration group.
(ii) Chronic myeloid leukemia
Autologous bone marrow transplantation is ineffective for chronic myeloid leukemia, and allogeneic bone marrow transplantation is the best choice.
Autologous bone marrow transplantation has a good therapeutic effect on malignant lymphoma, so it has become an indispensable treatment for malignant lymphoma. According to statistics, 1992, there were 3399 cases of autologous bone marrow transplantation in 26 countries in Europe, including malignant lymphoma 1394 cases, which was the first of all diseases. Only 123 cases of lymphoma received allogeneic bone marrow transplantation at the same time. In North America, 5492 cases of malignant lymphoma (652 cases of Hodgkin, 65438 cases of non-Hodgkin's lymphoma +04 17 cases) are also more than other diseases such as leukemia between autologous bone marrow transplantation 1992- 1993.
(1) Hodgkin's lymphoma
Most Hodgkin's disease can be completely relieved or even cured by first-line routine treatment, but there are still 20-50% patients who cannot get complete remission or relapse after remission. Without effective treatment, the prognosis of such patients is very poor. After recurrence, the survival rate of patients treated with the original first-line treatment scheme (such as MOPP) is generally less than 10-20%, and the first complete recovery is slightly better than 1 year. The efficacy of radiotherapy or non-cross-resistant regimen is also limited, and the 5-year disease-free survival rate (DFS) is less than 10%. General treatment is even worse for patients with recurrent and drug resistance. High dose chemotherapy plus autologous bone marrow transplantation can significantly improve the long-term survival rate. Chopra et al. treated HD 155 cases with EAMB pretreatment autologous bone marrow transplantation with poor prognosis (including 46 cases of primary drug resistance, 7 cases of partial remission, 52 cases of recurrence within 1 year, 37 cases of secondary recurrence and 3 cases of tertiary recurrence 13 cases). Results The transplant-related mortality was 10%, with no progress and no 5-year survival. Peece et al. performed two courses of conventional chemotherapy on 58 HD patients who relapsed for the first time, and then pretreated with CBV cisplatin. The median follow-up time after autologous bone marrow transplantation was 2.3 years, and PFS was 64%. General symptoms, extranodal diseases or complete remission period less than 65,438+0 years at the time of recurrence are unfavorable prognostic factors: none, one, two and three three-year PFS are 65,438+000%, 865,438+0%, 40% and 0% respectively. In addition, the prognosis of patients with tumor mass >: 10cm and more than three lines of treatment is also poor. In order to further prove that autologous bone marrow transplantation is superior to common treatment schemes, British scholars conducted a group study on 40 cases of recurrent and refractory HD. 20 cases were treated with ordinary dose EAMB, and 20 cases were treated with EAMB.
High dose radiotherapy and autologous bone marrow transplantation were used. Results The 3-year disease-free survival rate of transplantation group was 53%, and that of non-transplantation group was 65,438 00%. There was significant difference between the two groups.
It is still controversial whether autologous bone marrow transplantation should be performed immediately for the first recurrent HD, but Armitage is equal to 1994. The article points out that since the curative effect of autologous bone marrow transplantation in the treatment of recurrent HD is better than that of ordinary chemotherapy, and the related mortality rate of autologous bone marrow transplantation has dropped below 10%, once HD recurs, high-dose chemotherapy plus autologous bone marrow transplantation should be used regardless of the length of the first complete remission period.
(ii) Non-Hodgkin's lymphoma
Although the effective rate of non-Hodgkin's lymphoma (NHL) patients with poor response to first-line treatment or recurrence of moderate or high malignant NHL can reach 20-60%, it rarely achieves lasting remission. Gale et al. pointed out that there are more than 1000 such patients in the literature, and their 2-year survival rate is
Death in solution. At 28 months, DFS was as high as 85%. The authors believe that autologous bone marrow transplantation, as a consolidation therapy for NHL with high recurrence risk, can significantly improve the long-term survival rate of such patients after complete remission. The Spanish lymphoma cooperative group reported that 46 cases of NHL underwent autologous bone marrow transplantation in the first complete remission stage, and the DFS reached 75% in 8 years, and the recurrence rate was only 15%. Patients in the first complete remission stage are generally in good condition, so the transplant-related mortality rate is significantly lower than that of patients in the advanced stage, and the recurrence rate after transplantation is also low because tumor cells are not drug-resistant. Prognostic factors of moderately and highly malignant NHL are tumor mass >: 10cm, higher lactate dehydrogenase than normal, more than the second remission, drug resistance and so on. , but there is no significant difference in organization types.
Most of the low-grade NHL have a course of 7- 10 years, and autologous bone marrow transplantation is rarely used. However, if the complete remission or partial remission period is shorter than 1 year, the median survival time is only 2.4 years, and the prognosis of patients with moderate or high malignant transformation is even worse. Scholars have begun to explore the use of autologous bone marrow to treat low-grade NHL with poor prognosis, but there are few cases, so it is difficult to evaluate its curative effect at present.
Third, multiple myeloma.
The general effective rate of chemotherapy for multiple myeloma is about 50%, but the complete remission rate is less than 10%, and the median survival time is about 3 years. Although allogeneic bone marrow transplantation can cure diseases, few patients can inject allogeneic bone marrow transplantation because of their age at onset. McElwain et al. discovered in 1980s that high-dose Maffarin can improve the curative effect of multiple myeloma, but because of the long bone marrow suppression period, the treatment-related mortality rate is high. After that, they used autologous bone marrow transplantation, that is, VAMP (vincristine, adriamycin, methylprednisolone) was given to patients for several courses to reduce myeloma cells. After the above treatment, the number of tumor cells in bone marrow of 28 cases (24 cases) of 50 patients decreased to less than 30%.
Fourth, non-hematopoietic tumors.
Autologous hematopoietic stem cell transplantation (bone marrow or peripheral blood stem cells) is expected to greatly increase the dose of solid tumors sensitive to chemotherapy or radiotherapy, thus improving the survival rate of patients with poor prognosis after conventional treatment. In recent years, many tumor treatment units have carried out high-dose chemotherapy supported by autologous bone marrow for some recurrent and refractory solid tumors. According to the American Autologous Blood and Bone Marrow Registry, 1992- 1993 * * Autologous transplantation was performed in 5,496 cases, including 2,492 solid tumors. Among all kinds of tumors, breast cancer is the most, with *** 1938 cases, followed by neuroblastoma, testicular cancer, ovarian cancer and brain tumor.
Conventional treatment of stage IV and recurrent and refractory breast cancer is ineffective. Since 1980s, people began to explore high-dose chemotherapy combined with autologous bone marrow transplantation to treat such patients. Antman and Gale summarized the effect of autologous bone marrow transplantation in 326 cases of stage IV breast cancer in the late 1980s. With or without radiotherapy, the effective rate of stage ⅳ refractory breast cancer increased to 465,438+0-75%, the complete remission rate was only 65,438+0-65,438+05%, and the effective period was short. Autologous bone marrow transplantation as the first-line treatment of stage ⅳ breast cancer, the effective rate is 78%, the complete remission rate is as high as 56%, but the sustained remission rate is only 16%. If stage ⅳ breast cancer is given several courses of induction chemotherapy before transplantation, the effective rate is as high as 90%, and the complete remission rate is 765,438+0%. Recently Peters reported 5 18 cases, 65438+. Although there are still different opinions due to the lack of randomized controlled studies, at present, most people advocate that if there are adverse prognostic factors (such as primary lesions >; 10cm, metastatic lymph nodes >: 10 cases of breast cancer, inflammatory breast cancer, negative estrogen receptor, etc. High dose chemotherapy and autologous hematopoietic stem cell transplantation (peripheral blood or bone marrow) should be carried out after routine tumor reduction treatment to improve the radical cure rate.
Neuroblastoma is more common in children. In the past 15 * *, the European cooperation group carried out more than 700 cases of autologous bone marrow transplantation. 550 cases of stage ⅳ neuroblastoma 1 year-old, after the first complete remission, the 2-year and 5-year survival rates reached 52% and 29% respectively, which were better than those of general treatment (
First, acute leukemia
Second, chronic myeloid leukemia
Third, malignant lymphoma:
Four, multiple myeloma:
Five, myelodysplastic syndrome (MDS)
Six, severe aplastic anemia (SAA)
Seven. Others:
First, leukemia
Second, malignant lymphoma
Bone marrow transplantation violates physiological and natural laws.
Bone marrow transplantation is an advanced therapy initiated by modern international orthodox medicine, but the effect is very poor. This kind of therapy can basically be said to be a failure, because life not only has its body, but also has a super-body, super-material mind and spirit. Life is a small world and a "whole-body embryo" of the universe; Physiology originates from the origin of life and the evolution of hundreds of millions of years. It is closely related to nature and follows the universal causal natural law. Therefore, the mystery of life is super-machine, and it cannot be dominated by any "macro" or "micro" scientific research results. We can't treat diseases as mechanical repairs and loading and unloading, and we can't design and calculate dialectical treatment as construction projects.
Destroyed the immunity of life
The biggest mistake of bone marrow transplantation is that in the process of transplantation, it destroys the immune and self-supporting functions of life, making it unable to play the role of "rejection" and the transplantation is successful. However, immunity is an important factor for life to survive through self-defense and a basic pillar for its development and growth. The destruction of immunity means that the root of the tree has been broken and no life can live normally.
Matching difficulty
Another important defect of bone marrow transplantation is that there are few bone marrow donors suitable for transplantation, because it is difficult to find bone marrow donors with the same HLA match. According to statistics, it only accounts for about 2/100000 of the masses, that is, about 2 out of100000 people; Moreover, even if people with the same match are found, they are often unwilling to supply because they are worried about the harm to the body after pulp extraction.
Autologous bone marrow transplantation is also a waste of energy.
Autologous bone marrow transplantation, pioneered by the medical community, is not limited by the source of donors, but this treatment not only wastes energy, but also seriously violates physiological laws. Because the patient's bone marrow is pathological, the so-called immature cells are a local phenomenon of the patient's overall disease and a symptom, not the source and pathogen. Even if the remaining immature cells are cleaned up, the overall situation of the patient has not improved, and the bone marrow used is also some lifeless tissues. How can it have the function of radically curing this disease?
The success rate is extremely low and the cost is extremely high.
In recent years, I have contacted many patients with bone marrow transplantation. They suffered cruel pain, some died because of transplant failure, some committed suicide in despair, some were transplanted successfully, but they soon relapsed. However, the cost of transplantation is staggering. In Chinese mainland, each case needs 200,000 to 300,000 RMB.
The side effects are too great, and the future troubles are endless.
There are still many adverse side effects of bone marrow transplantation that have not been correctly recognized by the medical profession, patients, family members and some people in society. I suggest a summary for your reference.
The patient is deformed, deteriorated and abnormal as a whole, losing normal and natural health beauty.
Shortening the life cycle is ignored by the medical community, and even can be said to be blind. If the average life cycle of a person's birth, growth, decline and old age is 80 years, then when he is 20 years old, he should still have a life limit of 60 years. If he suffers from leukemia, he will receive chemotherapy and bone marrow transplantation. Even though he has used a lot of protein, hormones and blood to alleviate his survival ... On the surface, his life cycle is greatly shortened, and the remaining 60 years of life resources are saved. This is a very serious situation that must be paid attention to by the relevant departments.
Lose the meaning of life: after chemotherapy or bone marrow implantation, immunity is destroyed and self-reliance function is lost. In order to prevent infection, doctors try to isolate themselves from the outside world, even put them in sterile rooms, and often disinfect, test blood, take bone marrow, conduct various tests, and often inject nutrients, tonics and anti-inflammatory drugs to maintain their lives. In this way, on the surface, they were given advanced equipment and scientific treatment, but in fact they were deprived of their lives. If you live in pain and ruthlessness for a long time like a prisoner, you will completely lose the meaning of being a man.
To sum up, it can be seen that although bone marrow transplantation is the most advanced treatment method in the international medical field, and even advertised as a radical cure for leukemia, it is actually the most cruel and overbearing treatment method, which will leave the most painful page in the international medical history!